No­vo helps birth start­up ad­vanc­ing an As­traZeneca castoff with $15M; Japan's Fu­ji Phar­ma wa­gers $50M on Alvotech's biosim­i­lars

→ With back­ing from No­vo Hold­ings and a drug from As­traZeneca, Aris­tea Ther­a­peu­tics is un­veil­ing a $15 mil­lion Se­ries A that will kick­start Phase II stud­ies of its lead pro­gram, RIST4721. James Mack­ay, who used to run As­traZeneca-ac­quired Ardea Bio­sciences, is the founder and CEO of the San Diego-based start­up. He’s stay­ing mum on de­tails about Aris­tea’s pipeline of treat­ments for se­ri­ous in­flam­ma­to­ry dis­eases, pre­fer­ring in­stead to high­light the com­bined ex­per­tise of his crew of ex-Ardea ex­ecs: John Mon­tana, SVP of de­vel­op­ment; Sara Mc­Cutchan, reg­u­la­to­ry af­fairs man­ag­er; and DeAnne Reid, di­rec­tor of op­er­a­tions. Ti­ba Aynechi and Ken Har­ri­son of No­vo Ven­tures are join­ing the board.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.